Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Sage Therapeutics's Dalzanemdor?
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Sage Therapeutics's Dalzanemdor?
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease. According to...